Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NeoIpower
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- NCT05104788 ↗
- Recruiting
- Peking University Cancer Hospital & Institute
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NeoIpower (resectable stage II–IIIB EGFR-mutant lung adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NeoIpower so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Single-Arm, Prospective Study of Neoadjuvant Icotinib With Chemotherapy for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable for Stage II to IIIB(N2) Non-small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Icotinib; Cisplatin; Carboplatin; Pemetrexed
- Arms
- Icotinib with platinum-based chemotherapy · Experimental
- Enrollment
- 27 (estimated)
- Primary outcomes
- Major Pathological Response (MPR)
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 25, 2021 (estimated)
- Primary completion
- Mar 1, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT05104788 · updated Nov 3, 2021